Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
01:49pm, Friday, 13'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI), with a price target of $40.00. The company's
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
01:49pm, Friday, 13'th Mar 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum
Flexion Therapeutics (FLXN) Gets a Buy Rating from Needham
10:28am, Friday, 13'th Mar 2020
Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed
Flexion Therapeutics (FLXN) Gets a Buy Rating from Needham
10:28am, Friday, 13'th Mar 2020
Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN – Research Report) today and set a price
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Results - Earnings Call Transcript
01:23am, Friday, 13'th Mar 2020
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2019 Results Conference Call March 12, 2020 05:00 PM ET Company Participants Jason Shandell - President Bill Pe
Amphastar Pharmaceuticals Inc (AMPH) Q4 2019 Earnings Call Transcript
12:30am, Friday, 13'th Mar 2020
AMPH earnings call for the period ending December 31, 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
10:05pm, Thursday, 12'th Mar 2020
Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
10:05pm, Thursday, 12'th Mar 2020
Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BRIEF-Amphastar Pharmaceuticals Reports Q4 Revenue Of $83.4 Mln
09:38pm, Thursday, 12'th Mar 2020
Amphastar Pharmaceuticals Inc:
Amphastar: 4Q Earnings Snapshot
09:08pm, Thursday, 12'th Mar 2020
RANCHO CUCAMONGA, Calif. (AP) _ Amphastar Pharmaceuticals Inc. (AMPH) on Thursday reported a fourth-quarter loss of $1 million, after reporting a profit in the same period a year earlier. The Rancho C
Amphastar: 4Q Earnings Snapshot
09:07pm, Thursday, 12'th Mar 2020
RANCHO CUCAMONGA, Calif. (AP) _ Amphastar Pharmaceuticals Inc. (AMPH) on Thursday reported a fourth-quarter loss of $1 million, after reporting a profit in the same period a year earlier.
The Rancho C
Amphastar Pharmaceuticals Q4 EPS $0.07 Down From $0.13 YoY, Sales $83.4M Down From $89.69M YoY
08:32pm, Thursday, 12'th Mar 2020Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019
08:05pm, Thursday, 12'th Mar 2020
Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, Calif., March 12, 2020 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:.
